Ozempic has gained immense popularity recently, contributing to Weight Watchers’ bankruptcy, while new competitors like Mounjaro and the oral pill Orforglipron emerge. Currently in trials, Orforglipron aims to treat Type 2 diabetes and obesity, showing potential for 16-pound weight loss over nine months, with ongoing benefits post-trial. Developed by Lilly, the pill could address the UK’s obesity crisis, where 16.8 million people are affected, although it carries risks including nausea and serious health concerns like kidney failure and pancreatitis.
